Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) EBT (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed EBT for 13 consecutive years, with -$3.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 278.7% year-over-year to -$3.0 million, compared with a TTM value of -$7.6 million through Dec 2025, down 40.73%, and an annual FY2025 reading of -$8.4 million, down 55.56% over the prior year.
  • EBT was -$3.0 million for Q4 2025 at Abvc Biopharma, down from -$1.3 million in the prior quarter.
  • Across five years, EBT topped out at -$487076.0 in Q3 2024 and bottomed at -$6.2 million in Q1 2022.
  • Average EBT over 5 years is -$2.4 million, with a median of -$2.1 million recorded in 2021.
  • The sharpest move saw EBT tumbled 395.41% in 2022, then skyrocketed 85.54% in 2024.
  • Year by year, EBT stood at -$5.9 million in 2021, then skyrocketed by 39.93% to -$3.5 million in 2022, then surged by 85.16% to -$524999.0 in 2023, then crashed by 51.72% to -$796527.0 in 2024, then tumbled by 278.7% to -$3.0 million in 2025.
  • Business Quant data shows EBT for ABVC at -$3.0 million in Q4 2025, -$1.3 million in Q3 2025, and -$2.3 million in Q2 2025.